Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Diamyd Medical AB's Shareholder Yield % was 0.00%.
Diamyd Medical AB (OSTO:DMYD B) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Diamyd Medical AB Shareholder Yield % Related Terms
Diamyd Medical AB Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Diamyd Medical AB's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:DMYD B vs VRTX, REGN, RVMD: Shareholder Yield % Comparison
For the Biotechnology subindustry, Diamyd Medical AB's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamyd Medical AB Shareholder Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Diamyd Medical AB's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Diamyd Medical AB (OSTO:DMYD B) has a Shareholder Yield % of 0.00% as of May. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Diamyd Medical AB and its competitors. According to the industry distribution chart, Diamyd Medical AB ranks #999999 out of 1286 companies in the Biotechnology industry.
Is Diamyd Medical AB's Shareholder Yield % too high?
Diamyd Medical AB's current Shareholder Yield % is 0.00%. Based on the distribution chart, Diamyd Medical AB ranks #999999 out of 1286 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Diamyd Medical AB has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's Shareholder Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Diamyd Medical AB ranks #999999 out of 1286 companies for Shareholder Yield %. This places Diamyd Medical AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Diamyd Medical AB and its competitors. Diamyd Medical AB's current Shareholder Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Diamyd Medical AB (OSTO:DMYD B) is currently considered Possible Value Trap. The stock's GF Value™ is kr13.67, compared to a current price of kr1.01 — trading 92.6% below its estimated fair value. The current Shareholder Yield % is 0.00%. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Diamyd Medical AB (OSTO:DMYD B), the current Shareholder Yield % is 0.00% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diamyd Medical AB (OSTO:DMYD B) Overvalued in 2026?
Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be undervalued.
The current stock price of kr1.01 is trading 92.6% below its estimated GF Value™ of kr13.67.
GuruFocus considers Diamyd Medical AB to be Possible Value Trap.
Key valuation signals for OSTO:DMYD B:
Shareholder Yield %: 0.00%
GF Value™: kr13.67 vs. price of kr1.01 (92.6% below fair value)
No single metric tells the full story. See the OSTO:DMYD B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score
Get the complete analysis for OSTO:DMYD B
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:DMYD B has been successfully added to your 
